The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases.

scientific article published on 31 January 2014

The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1017/S1461145714000029
P8608Fatcat IDrelease_o5gv3nvozzbote3htgkwu4qoti
P698PubMed publication ID24485144
P5875ResearchGate publication ID260022619

P50authorMaría Rodríguez-MuñozQ42872732
Javier BurguenoQ114780783
Daniel ZamanilloQ122981817
P2093author name stringJavier Garzón
Pilar Sánchez-Blázquez
Raquel Herrero-Labrador
P2860cites workMorphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteinsQ21223665
What causes the onset of psychosis?Q22251464
Generation and phenotypic analysis of sigma receptor type I (σ1) knockout miceQ28184848
CB1 cannabinoid receptors and on-demand defense against excitotoxicityQ28207143
Antagonism of NMDA receptors by sigma receptor ligands attenuates chemical ischemia-induced neuronal death in vitroQ28215676
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaQ28240120
Causal association between cannabis and psychosis: examination of the evidenceQ28241735
Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survivalQ28255981
Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trialQ28286363
Activation of mu-opioid receptors transfers control of Galpha subunits to the regulator of G-protein signaling RGS9-2: role in receptor desensitizationQ28301079
sigma receptor ligands attenuate N-methyl-D-aspartate cytotoxicity in dopaminergic neurons of mesencephalic slice culturesQ28369929
Mice with reduced NMDA receptor expression display behaviors related to schizophreniaQ28510751
Neuroactive Steroids are Altered in Schizophrenia and Bipolar Disorder: Relevance to Pathophysiology and TherapeuticsQ29011855
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergenceQ29618819
Characterization of the human sigma-1 receptor chaperone domain structure and binding immunoglobulin protein (BiP) interactionsQ30646785
Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor bindingQ33754837
Modulation of NMDA and AMPA-mediated synaptic transmission by CB1 receptors in frontal cortical pyramidal cellsQ33923685
Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitizationQ34260033
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).Q34287318
From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatmentQ34632695
Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticityQ34691684
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disordersQ34795242
Risk for schizophrenia--broadening the concepts, pushing back the boundariesQ36187809
NMDA receptors and schizophrenia.Q36650010
Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactionsQ36756365
Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopmentQ36899309
Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old ratsQ36980744
Is the histidine triad nucleotide-binding protein 1 (HINT1) gene a candidate for schizophrenia?Q37312173
HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activityQ37364657
Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neuronsQ37444391
The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophreniaQ37583070
The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophreniaQ37872844
Sigma-1 receptors: potential targets for the treatment of substance abuseQ37979827
Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance.Q38037679
Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophreniaQ38340511
Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia.Q38340750
Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptorQ38358854
Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary studyQ38362304
The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control.Q39904357
Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid toleranceQ41070625
Effects of NMDA receptor blockade and nitric oxide synthase inhibition on the acute and chronic actions of delta 9-tetrahydrocannabinol in miceQ41664976
Pharmacological effects produced by intracerebral injection of drugs in the conscious mouseQ41949285
Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphineQ41958365
Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore.Q42670368
Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate.Q42872711
Involvement of direct inhibition of NMDA receptors in the effects of sigma-receptor ligands on glutamate neurotoxicity in vitroQ43506948
Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophreniaQ44167706
The histidine triad nucleotide-binding protein 1 supports mu-opioid receptor-glutamate NMDA receptor cross-regulationQ44348688
Testing hypotheses about the relationship between cannabis use and psychosisQ44487800
N-methyl-D-aspartate-induced neuronal activation is selectively modulated by sigma receptorsQ44728971
Molecular determinants of ligand discrimination in the glutamate-binding pocket of the NMDA receptorQ45157391
Characterization of the cocaine binding site on the sigma-1 receptorQ46151664
Molecular mechanisms of cannabinoid protection from neuronal excitotoxicityQ46813276
Sigma receptors in schizophrenic cerebral corticesQ48429016
Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects.Q51909816
Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis UsersQ57403275
Selective loss of cerebral cortical Sigma, but not PCP binding sites in schizophreniaQ67913940
Distinct neuroprotective profiles for sigma ligands against N-methyl-D-aspartate (NMDA), and hypoxia-mediated neurotoxicity in neuronal culture toxicity studiesQ72347007
Supportive evidence for the association between the Gln2Pro polymorphism in the SIGMAR1 gene and schizophrenia in the Japanese population: a case-control study and an updated meta-analysisQ84594757
P433issue12
P921main subjectCNR2Q17907844
psychosisQ170082
cannabinoid receptorQ421237
cannabinoidsQ422936
P304page(s)1943-1955
P577publication date2014-01-31
P1433published inThe International Journal of NeuropsychopharmacologyQ7742309
P1476titleThe calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases.
P478volume17

Reverse relations

cites work (P2860)
Q58732614Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor
Q47299109Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis.
Q58851764Cocaine Blocks Effects of Hunger Hormone, Ghrelin, Via Interaction with Neuronal Sigma-1 Receptors
Q53443172Critical role of sigma-1 receptors in central neuropathic pain-related behaviours after mild spinal cord injury in mice.
Q60306762Dipentylammonium Binds to the Sigma-1 Receptor and Protects Against Glutamate Toxicity, Attenuates Dopamine Toxicity and Potentiates Neurite Outgrowth in Various Cultured Cell Lines
Q42317501Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction
Q55340475Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors.
Q52318138Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process.
Q41572995Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine
Q64889678Ligands Exert Biased Activity to Regulate Sigma 1 Receptor Interactions With Cationic TRPA1, TRPV1, and TRPM8 Channels.
Q90263450Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases
Q38896666Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain
Q47284001Schizophrenia and depression, two poles of endocannabinoid system deregulation
Q54977290Sigma 1 Receptor Antagonists Inhibit Manic-like Behaviors in Two Congenital Strains of Mice.
Q39158236Sigma-1 Receptor Antagonists: A New Class of Neuromodulatory Analgesics
Q53647635Sigma-1 Receptor and Pain.
Q41289215Sigma-1 and N-Methyl-d-Aspartate Receptors: A Partnership with Beneficial Outcomes
Q38262682The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders
Q38639528The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9.
Q34675713The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems.
Q43195386The σ1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control

Search more.